|
|
 Previous Article | Table of Contents | Next Article 
Enhanced hematopoietic growth factor production in an experimental
myeloproliferative syndrome
MC Le Bousse-Kerdiles, M Souyri, F Smadja-Joffe, V Praloran, C Jasmin and HJ Ziltener
Unite d'Oncogenese Appliquee, INSERM U268, Hopital Paul Brousse, Villejuif,
France.
The murine myeloproliferative syndrome induced by the myeloproliferative
sarcoma virus (MPSV) has numerous similarities to human primary
myelofibrosis. We have shown that medium conditioned by spleen cells of
MPSV-infected mice has the capacity to support the growth of primitive
blast cell colonies. The detection of this activity associated with MPSV
infection stimulated us to characterize the hematopoietins responsible for
this activity. Northern blot analysis showed a large increase, or
induction, of interleukin-6 (IL-6), granulocyte-macrophage
colony-stimulating factor (GM-CSF), macrophage- CSF (CSF-1), and
granulocyte-CSF (G-CSF) transcripts in the hematopoietic organs of
MPSV-infected mice; however, no IL-3 transcript could be detected in either
MPSV-infected or normal mice. Significant levels of IL-1 alpha, IL-6,
G-CSF, and CSF-1 bioactivities were found in the serum of MPSV-infected
mice, but not in controls. Additionally, analysis of medium conditioned by
spleen cells of MPSV-infected mice showed the presence of tumor necrosis
factor alpha bioactivity. The increased production of cytokines that are
able to stimulate pluripotent hematopoietic stem cells corroborates the
hypothesis of a possible involvement of hematopoietic growth factors in the
development of some myeloproliferative disorders.
Volume 79,
Issue 12,
pp. 3179-3187,
06/15/1992
Copyright © 1992 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Tefferi, J. Cortes, S. Verstovsek, R. A. Mesa, D. Thomas, T. L. Lasho, W. J. Hogan, M. R. Litzow, J. B. Allred, D. Jones, et al.
Lenalidomide therapy in myelofibrosis with myeloid metaplasia
Blood,
August 15, 2006;
108(4):
1158 - 1164.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Mesa, M. A. Elliott, G. Schroeder, and A. Tefferi
Durable Responses to Thalidomide-Based Drug Therapy for Myelofibrosis With Myeloid Metaplasia
Mayo Clin. Proc.,
July 1, 2004;
79(7):
883 - 889.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Giraudier, H. Chagraoui, E. Komura, S. Barnache, B. Blanchet, J. P. LeCouedic, D. F. Smith, F. Larbret, A.-L. Taksin, F. Moreau-Gachelin, et al.
Overexpression of FKBP51 in idiopathic myelofibrosis regulates the growth factor independence of megakaryocyte progenitors
Blood,
September 26, 2002;
100(8):
2932 - 2940.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
